PRESS RELEASE published on 12/29/2025 at 08:00, 8 months 12 days ago Informations privilégiées / Autres communiqués GenSight Biologics réalise une levée de fonds de près de €2,9 millions d’euros pour développer des thérapies géniques innovantes. La société vise le traitement des maladies neurodégénératives de la rétine Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Rétine
PRESS RELEASE published on 12/29/2025 at 08:00, 8 months 12 days ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 12/22/2025 at 07:05, 8 months 19 days ago GenSight Biologics Receives Compassionate Use Authorization for GS010/LUMEVOQ® in France Gene Therapy Rare Diseases Compassionate Use LHON Treatment ANSM Approval
BRIEF published on 12/22/2025 at 07:05, 8 months 19 days ago Issuance of a compassionate access authorization for GS010/LUMEVOQ® Gene Therapy GenSight Biologics NOHL ANSM Compassionate Access
BRIEF published on 12/22/2025 at 07:05, 8 months 19 days ago GenSight Biologics obtient une autorisation d'usage compassionnel pour GS010/LUMEVOQ® en France Thérapie Génique Maladies Rares Usage Compassionnel Traitement De La LHON Approbation ANSM
BRIEF published on 12/22/2025 at 07:05, 8 months 19 days ago Délivrance d'une autorisation d'accès compassionnel pour GS010/LUMEVOQ® Thérapie Génique GenSight Biologics NOHL Accès Compassionnel ANSM
PRESS RELEASE published on 12/22/2025 at 07:00, 8 months 19 days ago Inside Information / Other news releases GenSight Biologics receives Compassionate Use Authorization in France for GS010/LUMEVOQ® gene therapy indicated for ND4-LHON treatment France GenSight Biologics GS010/LUMEVOQ® Compassionate Use Authorization ND4-LHON
PRESS RELEASE published on 12/22/2025 at 07:00, 8 months 19 days ago Informations privilégiées / Autres communiqués GenSight Biologics obtient une autorisation d'accès compassionnel en France pour GS010/LUMEVOQ dans le traitement de la NOHL liée à la mutation ND4 Thérapie Génique GenSight Biologics NOHL GS010/LUMEVOQ Autorisation D'accès Compassionnel
BRIEF published on 11/13/2025 at 18:02, 9 months 27 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 11/13/2025 at 18:02, 9 months 27 days ago Franchissement de seuils par Heights Capital Management Obligations Convertibles Franchissement De Seuils GenSight Biologics Actions Et Droits De Vote Heights Capital
Published on 09/10/2026 at 22:25, 4 hours 41 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 11 hours 46 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 12 hours 6 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 12 hours 29 minutes ago Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall
Published on 09/11/2026 at 00:01, 3 hours 5 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 4 hours 26 minutes ago EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 4 hours 55 minutes ago flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 4 hours 59 minutes ago EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board
Published on 09/10/2026 at 19:30, 7 hours 36 minutes ago Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 7 hours 36 minutes ago Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 8 hours 56 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 9 hours 21 minutes ago COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 9 hours 23 minutes ago Déclaration d'actions et de droits de vote au 31.08.2026
